Literature DB >> 8719332

Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro.

N Nakao1, P Brundin, K Funa, O Lindvall, P Odin.   

Abstract

We have examined the effects of either brain-derived neurotrophic factor (BDNF), the BB-isoform of platelet-derived growth factor (PDGF-BB), or a combination of these growth factors on the survival and the morphological development of embryonic striatal neurons grown under serum-free culture conditions. Striatal neurons were identified using immunocytochemistry for "dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein with a molecular weight of 32 kilodalton" (DARPP-32). BDNF and PDGF-BB promoted the survival of DARPP-32-positive neurons, with the magnitude of their effects being comparable. A combination of these growth factors exerted no significant additive effects on cell survival. BDNF stimulated morphological differentiation of DARPP-32-containing neurons by increasing the length of neurites, the number of branching points on the neurites, and the soma area. By contrast, PDGF-BB increased the neurite length and the cell body area, but not the number of branching points. BDNF also protected striatal neurons from excitotoxicity induced by N-methyl-D-aspartate, whereas PDGF-BB had no effect under the same treatment conditions as those for BDNF. Thus, BDNF is trophic for striatal DARPP-32-containing neurons in vitro by enhancing the survival, morphological differentiation and resistance to excitotoxicity, and its mechanisms of action are probably different from those of PDGF-BB.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719332     DOI: 10.1016/0165-3806(96)83489-4

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  24 in total

1.  An embryonic culture system for the investigation of striatal medium spiny neuron dendritic spine development and plasticity.

Authors:  Rachel D Penrod; Saïd Kourrich; Esther Kearney; Mark J Thomas; Lorene M Lanier
Journal:  J Neurosci Methods       Date:  2011-06-13       Impact factor: 2.390

2.  Glutamatergic Innervation onto Striatal Neurons Potentiates GABAergic Synaptic Output.

Authors:  Foteini Paraskevopoulou; Melissa A Herman; Christian Rosenmund
Journal:  J Neurosci       Date:  2019-04-01       Impact factor: 6.167

3.  BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.

Authors:  A Reiner; H B Wang; N Del Mar; K Sakata; W Yoo; Y P Deng
Journal:  Brain Res       Date:  2012-07-20       Impact factor: 3.252

4.  The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology.

Authors:  Joost Schulte; J Troy Littleton
Journal:  Curr Trends Neurol       Date:  2011-01-01

5.  Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.

Authors:  Chi-Tso Chiu; Guangping Liu; Peter Leeds; De-Maw Chuang
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 6.  Cellular therapy and induced neuronal replacement for Huntington's disease.

Authors:  Abdellatif Benraiss; Steven A Goldman
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 7.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

8.  Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease.

Authors:  Sung-Rae Cho; Abdellatif Benraiss; Eva Chmielnicki; Amer Samdani; Aris Economides; Steven A Goldman
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  Phosphatidylinositide 3-kinase and protein kinase C zeta mediate retinoic acid induction of DARPP-32 in medium size spiny neurons in vitro.

Authors:  Steve Pedrini; Alexey Bogush; Michelle E Ehrlich
Journal:  J Neurochem       Date:  2008-05-11       Impact factor: 5.372

Review 10.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.